Home | Publications | Diseases | Cancer place holder
place holder place holder

Cancer

Antibody Drug Target Atlas in Oncology


Publication Date   June 2007
Publisher   Bioseeker
Product Type  
Pages   172
ISBN Number   not applicable
Product Code   BSK159
Ask a question about this product?

Price £2,330.00

approximately: $4,354 | €2,955

Summary


The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in development for the treatment of cancer. What and where they are targeting has to date only been a fragmented knowledge. First in place, BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. Drug targets and their associated antibodies have been analyzed by BioSeeker according to:

  • 34 Different molecular functions of target
  • 13 Major signaling pathways
  • Cancer stem cells
  • Conjugated antibodies
  • Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
  • 31 Targeted cancer indications
  • Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
  • Antibody therapeutic companies
  • Single target analysis of the 132 antibody targets is performed, including targeted cancer indications, antibody drugs involved and their developmental stages. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.

This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.

Content


  • About BioSeeker
  • Executive Summary
  • Methodology
  • Abbreviations
  • Introduction
  • The Growing HIV Market
  • What to Expect From the HIV Pharmaceutical Companies
  • The Competitive Landscape of HIV Alliances
  • Companies Between Powerful Clusters- Are they of Strategic Value?
  • Vertex's Role as a Linker Between HIV Clusters
    • The HIV Cluster Analysis
    • The Major Cluster in HIV R&D
    • The Drug Discovery Cluster
    • The Swedish HIV Cluster
    • The Danish HIV Cluster
    • The Cluster that was Created in
    • The M&A cluster
    • The Late Stage Collaboration Cluster
  • Selected Company Profiles
  • Conclusion
  • Disclaimer
  • Appendix 1, Details on HIV Business Interactions,
  • List of Tables
    • Table 1. The prevalence among adults that are infected with HIV in Africa, 2003.
    • Table 2. The most common business interactions in the HIV field 1995-2004.
    • Table 3. Vertex's role as a linker between HIV clusters.
    • Table 4. The Major Cluster in HIV R&D
    • Table 5. The Drug Discovery Cluster
    • Table 6. The Swedish HIV Cluster
    • Table 7. The Danish HIV Cluster
    • Table 8. The Cluster that was Created in
    • Table 9. The M&A Cluster
    • Table 10. The Late Stage Collaboration Cluster
  • List of Figures
    • Figure 1. Adults and children living with HIV
    • Figure 2. Business interactions increase significant in
    • Figure 3. The Vertex cluster analysis
    • Figure 4. An Overview of the HIV Cluster analysis
    • Figure 5. The Major cluster in HIV R&D
    • Figure 6. The Drug Discovery Cluster
    • Figure 7. The Swedish HIV Cluster
    • Figure 8. The Danish HIV Cluster
    • Figure 9. The 2004 Cluster
    • Figure 10. The M&A cluster
    • Figure 11. The Late Stage Collaboration Cluster